We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · August 03, 2022

Abemaciclib Plus Tamoxifen in Patients With Endocrine-Refractory HR+/HER2– Metastatic Breast Cancer

Breast Cancer Research and Treatment


Additional Info

Breast Cancer Research and Treatment
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer
Breast Cancer Res Treat 2022 Jul 12;[EPub Ahead of Print], E Hamilton, J Cortes, O Ozyilkan, SC Chen, K Petrakova, A Manikhas, G Jerusalem, R Hegg, J Huober, W Zhang, Y Chen, M Martin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading